The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VCEL | -27.8% | +56.78% | +9.41% | -97% |
| S&P | +12.65% | +91.73% | +13.89% | +753% |
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $67.50M | 16.6% |
| Gross Profit | $49.59M | 19.0% |
| Gross Margin | 73.46% | 1.5% |
| Market Cap | $1.59B | -23.3% |
| Market Cap / Employee | $4.45M | 0.0% |
| Employees | 357 | 13.7% |
| Net Income | $5.07M | 663.2% |
| EBITDA | $6.39M | 661.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $100.40M | 42.7% |
| Accounts Receivable | $60.43M | 24.6% |
| Inventory | 18.2 | 15.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $85.83M | -6.3% |
| Short Term Debt | $13.96M | 128.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 3.10% | 2.1% |
| Return On Invested Capital | -1.46% | 2.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $19.45M | 310.9% |
| Operating Free Cash Flow | $22.08M | 116.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 297.45 | 1129.62 | 341.22 | 130.69 | -80.67% |
| Price to Book | 10.51 | 7.58 | 7.24 | 5.17 | -36.00% |
| Price to Sales | 12.08 | 9.33 | 8.60 | 6.31 | -30.94% |
| Price to Tangible Book Value | 10.77 | 7.75 | 7.39 | 5.28 | -36.36% |
| Price to Free Cash Flow TTM | 117.58 | 1230.01 | 80.17 | - | |
| Enterprise Value to EBITDA | 142.31 | -218.54 | 2669.78 | 249.92 | -113.86% |
| Free Cash Flow Yield | 0.9% | 0.1% | 1.2% | - | |
| Return on Equity | 4.0% | 1.1% | 2.6% | 4.5% | 193.95% |
| Total Debt | $99.84M | $100.93M | $101.54M | $99.80M | 2.14% |
No podcast episodes available.
VCEL earnings call for the period ending June 30, 2022.
VCEL earnings call for the period ending March 31, 2022.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
